[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,88,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100634355","the-gore-viabahn-fortegra-venous-stent-post-approval-study-100634355",false,"NCT07538609","The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study","Preoperative Inclusion Criteria:\n\n* Presence of a lesion necessitating treatment with the GORE® VIABAHN® FORTEGRA Venous Stent, as previously determined by an investigator\u002Fsub-investigator.\n* Patient is at least 18 years of age.\n* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.\n* Patient is able to provide informed consent themself.\n\nIntraoperative Inclusion Criteria:\n\n* Patient can accommodate an appropriately sized GORE® VIABAHN® FORTEGRA Venous Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.\n* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.\n* Patient has adequate landing zones free from significant disease requiring treatment beyond the proximal and distal margins of the lesion.\n* Patient has adequate inflow\u002Foutflow to\u002Ffrom the target lesion(s), per investigator\u002Fsub- investigator discretion.\n* Lesion can be traversed with a guidewire.\n\nIntraoperative Exclusion Criteria:\n\n* Patient is contraindicated for treatment with the GORE® VIABAHN® FORTEGRA Venous Stent according to the IFU.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is a prospective, multicenter, single-arm post-market clinical study to evaluate the GORE® VIABAHN® FORTEGRA Venous Stent in real-world use.",[25,26,27,28,29,30,31,32],"Venous Thromboses","Venous Disease","Venous Leg Ulcer","Venous Stasis","Venous Ulcer","Venous Stenosis","Venous Occlusion","Vein Thrombosis",[34,35,36,30,37,38,39,40,41,42,26,43,44,45,46],"Vein Stent","VIAFORT","Venous Thrombosis","Gore","Venous occlusion","VIABAHN FORTEGRA","FORTEGRA","Deep Venous Insufficiency","Deep venous","DVT Treatment","Venous Stent","Venous insufficiency treatment options","Venous disease treatment options","NOT_YET_RECRUITING","2026-08-11",{"date":50,"type":51},"2026-08-12","ACTUAL",{"date":53,"type":19},"2026-10-07",{"date":55,"type":19},"2031-05",{"name":57,"class":58},"W.L.Gore & Associates","INDUSTRY",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":16,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100640028","assessment-of-venous-insufficiency-and-clinical-features-in-lipedema-100640028","NCT07603076","Assessment of Venous Insufficiency and Clinical Features in Lipedema","Evaluation of Venous Insufficiency and Its Association With Clinical Features in Patients With Lipedema: A Cross-Sectional Study","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Clinically diagnosed lipedema according to established diagnostic criteria\n* Ability to provide written informed consent\n* Ability to complete clinical assessments and questionnaires\n\nExclusion Criteria:\n\n* History of lower extremity venous surgery or sclerotherapy\n* Known peripheral arterial disease\n* Secondary lymphedema or other causes of lower extremity edema\n* Active infection, cellulitis, or inflammatory disease affecting the lower extremities\n* Pregnancy or postpartum period\n* Neurological, rheumatological, or musculoskeletal disorders significantly affecting lower extremity function\n* Malignancy or severe systemic disease\n* Inability to undergo venous Doppler ultrasonography\n* Inability to understand or complete study assessments and questionnaires","FEMALE","65 Years",{"count":69,"type":19},82,"OBSERVATIONAL","Lipedema is a chronic adipose tissue disorder characterized by disproportionate fat accumulation, pain, tenderness, edema, and functional impairment. Venous symptoms such as heaviness, swelling, and discomfort are frequently reported in individuals with lipedema; however, the relationship between venous Doppler ultrasonography findings and lipedema-related clinical manifestations remains insufficiently investigated. This cross-sectional controlled study aims to evaluate venous insufficiency parameters in patients with lipedema using Doppler ultrasonography and to examine their associations with pain severity, lower extremity function, disease severity, and quality of life.",[73,74,26,75],"Lipedema","Venous Insufficiency","Disability Physical","RECRUITING","2026-07-13",{"date":79,"type":51},"2026-07-14",{"date":81,"type":51},"2026-06-20",{"date":83,"type":19},"2026-08-01",{"name":85,"class":86},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","OTHER",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100443162","us-post-market-surveillance-study-of-the-surfacer-system-100443162","NCT05050799","US Post-Market Surveillance Study of the Surfacer System","US Post-Market Surveillance Study of the Surfacer* Inside-Out* Access Catheter System (Surfacer System)","Inclusion Criteria:\n\n1. Subjects have been referred for placement of central venous access, i.e., placement of catheter, nutritional line, etc.\n2. Subjects with upper body venous occlusions or other conditions that preclude central venous access by conventional methods\n3. Subjects are willing and able to give written informed consent\n\nExclusion Criteria:\n\n1. Occlusion of the right femoral vein, right iliac vein or inferior vena cava\n2. Acute thrombus within any vessel to be crossed by Surfacer System (SVC, jugular, IVC, brachiocephalic and subclavian)\n3. Occlusion within the arterial system\n4. Occlusion within the coronary or cerebral vasculature",{"count":96,"type":19},30,"Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.",[26],"2026-05-28",{"date":101,"type":51},"2026-06-01",{"date":103,"type":51},"2022-02-08",{"date":105,"type":19},"2026-12-15",{"name":107,"class":58},"Merit Medical Systems, Inc.",9,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":87},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":117,"type":19},500,"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[120,121,122,123,124,26,125,126,73,127,128,129,130,131,132,133],"Cardiovascular Diseases","Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Thrombosis","Lymphedema","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Vasculitis","Fibromuscular Dysplasia","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":136,"type":51},"2025-12-19",{"date":138,"type":51},"2019-11-14",{"date":140,"type":19},"2031-06-30",{"name":142,"class":86},"The Cleveland Clinic"]